“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial”, J of Skin, vol. 7, no. 6, p. s239, Nov. 2023, doi: 10.25251/skin.7.supp.239.